Fernando Franco1, Enric Carcereny2, Maria Guirado3, Ana L Ortega4, Rafael López-Castro5, Delvys Rodríguez-Abreu6, Rosario García-Campelo7, Edel Del Barco8, Oscar Juan9, Francisco Aparisi10, Jose L González-Larriba11, Manuel Domine12, Jose M Trigo13, Manuel Cobo13, Sara Cerezo14, Julia Calzas15, Bartomeu Massutí16, Joaquim Bosch-Barrera17, Paola García Coves3, Marta Domènech2, Mariano Provencio1. 1. Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. 2. Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, B-ARGO, IGTP, Badalona, Spain. 3. Hospital General Universitario de Elche, Elche, Spain. 4. Hospital Universitario de Jaén, Jaén, Spain. 5. Hospital Clínico Universitario de Valladolid, Valladolid, Spain. 6. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. 7. Complejo Hospitalario Universitario A Coruña, A Coruña, Spain. 8. Hospital Universitario de Salamanca, Salamanca, Spain. 9. Hospital Universitario y Politécnico La Fe, Valencia, Spain. 10. Hospital General de Valencia, Valencia, Spain. 11. Hospital Universitario Clínico San Carlos, Madrid, Spain. 12. Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain. 13. Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. 14. Hospital General La Mancha Centro, Alcázar de San Juan, Spain. 15. Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. 16. Hospital General Universitario de Alicante, Alicante, Spain. 17. Catalan Institute of Oncology, Girona, Spain.
Abstract
BACKGROUND: Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce. PATIENTS AND METHODS: This was an observational multicenter study that enrolled patients with lung cancer and thoracic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demographic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed. RESULTS: With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or ≥ 2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty percent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overall survival was 9.5 months (95% CI 8.8-10.2 months), with an estimated rate of 70.3% (95% CI 67.2-73.4%), 38.9% (95% CI 35.4-42.4%), and 14.8% (95% CI 11.8-17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mortality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1-2. Long-term survival (> 2 years) was confirmed in 6.6% of patients, showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis. CONCLUSION: This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients.
BACKGROUND:Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLCpatients retrieved from lung cancer registries is scarce. PATIENTS AND METHODS: This was an observational multicenter study that enrolled patients with lung cancer and thoracic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demographic and clinical data, treatment patterns and survival of SCLCpatients included in the Thoracic Tumor Registry (TTR) were analyzed. RESULTS: With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or ≥ 2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty percent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overall survival was 9.5 months (95% CI 8.8-10.2 months), with an estimated rate of 70.3% (95% CI 67.2-73.4%), 38.9% (95% CI 35.4-42.4%), and 14.8% (95% CI 11.8-17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mortality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1-2. Long-term survival (> 2 years) was confirmed in 6.6% of patients, showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis. CONCLUSION: This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients.